Armocad 1mg Tablet

About

Armocad 1mg Tablet is an oral medication classified as an aromatase inhibitor, primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by selectively inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogens in peripheral tissues. In postmenopausal women, estrogen production primarily occurs through this pathway, as ovarian estrogen production ceases. By significantly reducing estrogen levels, Armocad helps to suppress the growth of estrogen-dependent breast cancer cells. This mechanism makes it an effective adjuvant therapy following surgery or as a first-line treatment for advanced disease, offering a crucial therapeutic option to prevent recurrence and manage metastatic breast cancer.

Uses

• Adjuvant treatment of early hormone receptor-positive breast cancer.
• First-line treatment of hormone receptor-positive advanced breast cancer.
• Treatment of advanced breast cancer after tamoxifen therapy.
• Prevention of breast cancer recurrence in high-risk postmenopausal women.

Directions For Use

Take one tablet orally once daily, with or without food, as prescribed by your doctor.

Benefits

• Significantly reduces estrogen levels.
• Inhibits growth of hormone-sensitive tumors.
• Reduces risk of breast cancer recurrence.
• Effective in advanced and early-stage disease.
• Oral administration for convenience.
• Improves disease-free survival.

Side Effects

• Hot flashes
• Joint pain (arthralgia)
• Fatigue
• Nausea
• Headache
• Bone thinning (osteoporosis)
• Vaginal dryness
• Hair thinning
• Weight gain
• Mood disturbances
• Peripheral edema
• Increased cholesterol levels

Safety Measures

• Alcohol - No specific interaction, but excessive alcohol intake is generally discouraged in cancer patients.
• Pregnancy - Contraindicated in pregnant women due to potential harm to the fetus.
• Breastfeeding - Contraindicated during breastfeeding as it may harm the infant.
• Liver - Use with caution in patients with severe hepatic impairment; dose adjustment may be necessary.
• Kidney - Generally safe in patients with mild to moderate renal impairment; no dose adjustment typically required.
• Lung - No specific precautions for lung conditions, but monitor for any new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.